AhmetDoganMDPhD, FRCPATH

PubMed

• Characterizing Nodal Gamma-Delta T-Cell Lymphoma: Clinicopathological and Molecular Insights.
  Ming Liang Oon, Jing Quan Lim, Jan Bosch-Schips, Fina Climent, Rex K H Au-Yeung
  Modern Pathology. 2024-12-13
• Phase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Up...
  Eric M Jurgens, Ross S Firestone, Jagrutiben Chaudhari, Kinga Hosszu, Sean M Devlin
  Journal of Clinical Oncology. 2024-12-04
• Cyclin D1-negative and SOX11-positive B-cell lymphoma with CD5 and CD10 coexpression andrearrangement: A diagnostic challenge.
  Mingfei Yan, Yanming Zhang, Ahmet Dogan, Mariko Yabe
  Ejhaem. 2024-12-01

Journal Articles

• Novel Iatrogenic Amyloidosis Caused by Peptide Drug Liraglutide: A Clinical Mimic of AL Amyloidosis  
  Heather J Landau, Ahmet Dogan, Haematologica

Abstracts/Posters

• Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma
  Ahmet Dogan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Aberrant SYK Expression As a Potential Therapeutic Target in T/NK Cell Neoplasms
  Ahmet Dogan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Ph...
  Ahmet Dogan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Incidence of Delayed Seromas and Related Risk of Bia-ALCL in a Cohort of 3521 Breast Cancer Women with Textured Implants Prospectively Followed Long Term
  Ahmet Dogan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Contemporary Outcomes in HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: Single-Institution Experience
  Ahmet Dogan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Ph...
  Ahmet Dogan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple My...
  Ahmet Dogan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Central Nervous System Prophylaxis with High-Dose Intravenous Methotrexate or Intrathecal Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma and High-Risk of ...
  Ahmet Dogan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• CD4 Lymphocytes and T Regulatory Cells Show Distinct Phenotypes in Follicular Lymphoma and Classical Hodgkin Lymphoma Which May Account for Differences in Responses to...
  Ahmet Dogan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Genomic Profiling of Mantle Cell Lymphoma Suggests Poor-Risk Profile Is Present at Diagnosis and Does Not Arise By Tumor Evolution
  Ahmet Dogan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Annotation of Somatic Genomic Variants in Hematologic Diseases Using OncoKB, a Precision Oncology Knowledgebase
  Ahmet Dogan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• MRD-Response Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Circulating Lymphoma Cells in Mycosis Fungoides/Sezary Syndrome Show Heterogeneity of the Cell-of-Origin and Variable PD-1 Expression By Flow Cytometric Analysis 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018